-
Je něco špatně v tomto záznamu ?
Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study
DA. Pappas, F. Nyberg, JM. Kremer, K. Lampl, GW. Reed, L. Horne, M. Ho, A. Onofrei, AN. Malaviya, OL. Rillo, SC. Radominski, J. Gal, A. Gibofsky, TV. Popkova, L. Laurindo, EM. Kerzberg, R. Zahora, BA. Pons-Estel, JR. Curtis, DE. Furst, JD. Greenberg,
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články
NLK
ProQuest Central
od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-01-01 do Před 1 rokem
- MeSH
- hyperlipidemie epidemiologie MeSH
- hypertenze epidemiologie MeSH
- kardiovaskulární nemoci epidemiologie MeSH
- lidé MeSH
- prevalence MeSH
- prospektivní studie MeSH
- průřezové studie MeSH
- registrace MeSH
- revmatoidní artritida epidemiologie terapie MeSH
- rizikové faktory MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Argentina MeSH
- Brazílie MeSH
- Indie MeSH
- Mexiko MeSH
- Spojené státy americké MeSH
- východní Evropa MeSH
To compare the prevalence of cardiovascular disease (CVD) and major CVD risk factors among rheumatoid arthritis (RA) patients enrolled in a large US and multinational registry. We compared CVD and CVD risk factor prevalence from 11 countries enrolled in the CORRONA US and CORRONA International registries; patients from the 10 ex-US participating countries were grouped by region (Eastern Europe, Latin America, and India). Unadjusted summary data were presented for demographics and disease characteristics; comparisons for prevalence of CVD risk factors and CVD were age/gender standardized to the age/gender distribution of the US enrolled patients. Overall, 25,987 patients were included in this analysis. Compared to patients from the ex-US regions, US participants had longer disease duration and lower disease activity, yet were more likely to receive a biologic agent. Additionally, CORRONA US participants had the highest body mass index (BMI). Enrolled patients in India had the lowest BMI, were more rarely smokers, and had a low prevalence of hyperlipidemia, hypertension, and prior CVD compared to the US and other ex-US regions. Participants from Eastern Europe had a higher prevalence of hypertension and hyperlipidemia and highest prevalence of all manifestations of CVD. Differences in the prevalence of both CVD and major CVD risk factors were observed across the four regions investigated. Observed differences may be influenced by variations in both non-modifiable/modifiable characteristics of patient populations, and may contribute to heterogeneity on the observed safety of investigational and approved therapies in studies involving RA patients from different origins.
Albany Medical College and The Center for Rheumatology Albany NY USA
Cardiovascular Institute of Rosario Rosario Argentina
Clinical Global Medicines Development AstraZeneca R and D Alderley Park UK
Corrona LLC Southborough MA USA
Corrona LLC Southborough MA USA NYU School of Medicine New York NY USA
Corrona LLC Southborough MA USA University of Massachusetts Medical School Worcester MA USA
County Hospital Kecskemét Hungary
David Geffen School of Medicine at UCLA Los Angeles CA USA
Genentech Inc South San Francisco CA USA
Hospital 1 Pirovano Buenos Aires Argentina
Hospital for Special Surgery Weill Medical College of Cornell University Ithaca New York USA
ISIC Super Specialty Hospital New Delhi India
JM Ramos Mejía Hospital School of Medicine University of Buenos Aires Buenos Aires Argentina
Nasonova Research Institute of Rheumatology Moscow Russia
Revmatologická Ambulance Terezín Czech Republic
Universidade Federal do Paraná and CETI Curitiba Brazil
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19012705
- 003
- CZ-PrNML
- 005
- 20190411095944.0
- 007
- ta
- 008
- 190405s2018 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s10067-018-4113-3 $2 doi
- 035 __
- $a (PubMed)29696436
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Pappas, Dimitrios A $u Columbia University College of Physicians and Surgeons, New York, NY, USA. dpappas@corrona.org. Corrona LLC, Southborough, MA, USA. dpappas@corrona.org.
- 245 10
- $a Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study / $c DA. Pappas, F. Nyberg, JM. Kremer, K. Lampl, GW. Reed, L. Horne, M. Ho, A. Onofrei, AN. Malaviya, OL. Rillo, SC. Radominski, J. Gal, A. Gibofsky, TV. Popkova, L. Laurindo, EM. Kerzberg, R. Zahora, BA. Pons-Estel, JR. Curtis, DE. Furst, JD. Greenberg,
- 520 9_
- $a To compare the prevalence of cardiovascular disease (CVD) and major CVD risk factors among rheumatoid arthritis (RA) patients enrolled in a large US and multinational registry. We compared CVD and CVD risk factor prevalence from 11 countries enrolled in the CORRONA US and CORRONA International registries; patients from the 10 ex-US participating countries were grouped by region (Eastern Europe, Latin America, and India). Unadjusted summary data were presented for demographics and disease characteristics; comparisons for prevalence of CVD risk factors and CVD were age/gender standardized to the age/gender distribution of the US enrolled patients. Overall, 25,987 patients were included in this analysis. Compared to patients from the ex-US regions, US participants had longer disease duration and lower disease activity, yet were more likely to receive a biologic agent. Additionally, CORRONA US participants had the highest body mass index (BMI). Enrolled patients in India had the lowest BMI, were more rarely smokers, and had a low prevalence of hyperlipidemia, hypertension, and prior CVD compared to the US and other ex-US regions. Participants from Eastern Europe had a higher prevalence of hypertension and hyperlipidemia and highest prevalence of all manifestations of CVD. Differences in the prevalence of both CVD and major CVD risk factors were observed across the four regions investigated. Observed differences may be influenced by variations in both non-modifiable/modifiable characteristics of patient populations, and may contribute to heterogeneity on the observed safety of investigational and approved therapies in studies involving RA patients from different origins.
- 650 _2
- $a revmatoidní artritida $x epidemiologie $x terapie $7 D001172
- 650 _2
- $a kardiovaskulární nemoci $x epidemiologie $7 D002318
- 650 _2
- $a průřezové studie $7 D003430
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hyperlipidemie $x epidemiologie $7 D006949
- 650 _2
- $a hypertenze $x epidemiologie $7 D006973
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a prevalence $7 D015995
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a registrace $7 D012042
- 650 _2
- $a rizikové faktory $7 D012307
- 651 _2
- $a Argentina $x epidemiologie $7 D001118
- 651 _2
- $a Brazílie $x epidemiologie $7 D001938
- 651 _2
- $a východní Evropa $x epidemiologie $7 D005061
- 651 _2
- $a Indie $x epidemiologie $7 D007194
- 651 _2
- $a Mexiko $x epidemiologie $7 D008800
- 651 _2
- $a Spojené státy americké $x epidemiologie $7 D014481
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Nyberg, Fredrik $u Medical Evidence and Observational Research Centre, Global Medicines Development, AstraZeneca R&D, Mölndal, Sweden. Occupational and Environmental Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
- 700 1_
- $a Kremer, Joel M $u Albany Medical College and The Center for Rheumatology, Albany, NY, USA.
- 700 1_
- $a Lampl, Kathy $u Genentech Inc., South San Francisco, CA, USA.
- 700 1_
- $a Reed, George W $u Corrona LLC, Southborough, MA, USA. University of Massachusetts Medical School, Worcester, MA, USA.
- 700 1_
- $a Horne, Laura $u Medical Evidence and Observational Research Centre, Global Medicines Development, AstraZeneca R&D, Wilmington, DE, USA.
- 700 1_
- $a Ho, Meilien $u Clinical, Global Medicines Development, AstraZeneca R&D, Alderley Park, UK.
- 700 1_
- $a Onofrei, Alina $u Corrona LLC, Southborough, MA, USA.
- 700 1_
- $a Malaviya, Anand N $u ISIC Super Specialty Hospital, New Delhi, India.
- 700 1_
- $a Rillo, Oscar L $u Hospital I. Pirovano, Buenos Aires, Argentina.
- 700 1_
- $a Radominski, Sebastiao C $u Universidade Federal do Paraná and CETI, Curitiba, Brazil.
- 700 1_
- $a Gal, Janos $u County Hospital, Kecskemét, Hungary.
- 700 1_
- $a Gibofsky, Allan $u Hospital for Special Surgery-Weill Medical College of Cornell University, Ithaca, New York, USA.
- 700 1_
- $a Popkova, Tatiana V $u Nasonova Research Institute of Rheumatology, Moscow, Russia.
- 700 1_
- $a Laurindo, Leda $u University Nove De Julho, São Paulo, Brazil.
- 700 1_
- $a Kerzberg, Eduardo M $u JM Ramos Mejía Hospital, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina.
- 700 1_
- $a Zahora, Roman $u Revmatologická Ambulance, Terezín, Czech Republic.
- 700 1_
- $a Pons-Estel, Bernado A $u Cardiovascular Institute of Rosario, Rosario, Argentina.
- 700 1_
- $a Curtis, Jeffrey R $u University of Alabama at Birmingham, Birmingham, AL, USA.
- 700 1_
- $a Furst, Daniel E $u David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
- 700 1_
- $a Greenberg, Jeffrey D $u Corrona LLC, Southborough, MA, USA. NYU School of Medicine, New York, NY, USA.
- 773 0_
- $w MED00001162 $t Clinical rheumatology $x 1434-9949 $g Roč. 37, č. 9 (2018), s. 2331-2340
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29696436 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20190411100001 $b ABA008
- 999 __
- $a ok $b bmc $g 1392015 $s 1051010
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 37 $c 9 $d 2331-2340 $e 20180425 $i 1434-9949 $m Clinical rheumatology $n Clin Rheumatol $x MED00001162
- LZP __
- $a Pubmed-20190405
